Cellceutix Provides Update on Its Phase 3 Preparations for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellceutix Provides Update on Its Phase 3 Preparations for ABSSSI

BEVERLY, MA --(Marketwired - October 13, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that it continues to progress towards starting a phase 3 study for Brilacidin intravenous (IV) in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In September, Cellceutix submitted its initial Pediatric Study Plan (PSP) to the Food and Drug Administration (FDA) for the use of Brilacidin IV in the treatment of ABSSSI in children. Cellceutix agreed to submit the PSP during its end-of-phase 2 meeting with FDA in mid-July. The submission of the PSP is the first of many requirements in expanding the use of Brilacidin to children.

Cellceutix is engaged in other phase 3 start-up activities. For example, the Company recently received the Brilacidin active pharmaceutical (API) from its contracted manufacturer. The API which has already passed all quality control tests at the manufacturer is now undergoing additional rigorous laboratory testing by our vendors to make certain it's up to the standards we require for the drug. We will test it head-to-head with the product used in earlier studies. Thereafter, we will begin the process of preparing the formulation for the phase 3 clinical study by using lyophilization. Lyophilization is a freeze-drying process that makes the drug more stable at room temperature, which has benefits for storage, transportation and administration. In addition, the Company is continuing its interviews of leading sites and Contract Research Organizations (CROs) that have experience conducting global ABSSSI studies.

"As the manufacturing process of Brilacidin for the phase 3 trial is the final product that would be used for commercialization should the trial be successful and all regulatory marketing approvals be obtained in the future, we are conscientious to ensure it is exactly what we want it to be," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We know of companies that failed to be meticulous in this matter heading into a pivotal trial and it has come back on them; that's a mistake we don't intend to make."

Brilacidin, the first in a new class of immunomodulatory antibiotics known as Host Defense Protein (HDP) mimics, has potent activity against Staphylococcus aureus , including methicillin-resistant S. aureus (MRSA). Brilacidin received Qualified Infectious Disease Product (QIDP) designation under the GAIN Act in November 2014.

The goal of phase 3 is to confirm the safety and efficacy of single-dose Brilacidin IV against a commonly used antibiotic in large groups of ABSSSI patients worldwide. Because of its novel structure, unique killing properties, and ability to be given as a single-dose, Cellceutix believes Brilacidin IV presents a significant market opportunity in ABSSSI. Brilacidin has the potential to mimimize the burden of antimicrobial resistance, relative to approved ABSSSI compounds, and its anti-inflammatory activity may promote the clinical resolution or healing of skin lesions. Cellceutix plans to use ABSSSI as a gateway to other indications in areas of unmet medical need. This includes, but is not limited to, biofilm-related infections caused by MRSA.

Cellceutix also wishes to announce that next week it will be updating its shareholders about its Proxy as well as the Annual Meeting planned for December 2015.

Alerts: Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs

Cellceutix clinical trials on Clinicaltrials.gov: https://clinicaltrials.gov/ct2/results?term=c...rch=Search

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 100

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

Kochav Defense Offers Class A Shares for Independent Trading

Updated Category News Views 100

Kochav Defense Initiates Separate Trading of Class A Shares Kochav Defense Acquisition Corp. (NASDAQ: KCHVU) has exciting news for its investors! Starting July 21, 2025, holders of the unit shares sold during its initial public offering will have the option to trade their Class A ordinary shares and rights separately. This development is expected to provide additional...

Continue Reading
CITGO Takes Active Steps in Community Safety Drills

Updated Category News Views 234

CITGO Lake Charles Refinery completed a significant emergency response drill back in 2024, engaging over 130 participants including local, state, and federal emergency responders. This Worst-Case scenario drill simulated operations on the waterway to bolster command capabilities during potential environmental incidents. Emergency Preparedness: The Core of CITGO's...

Continue Reading
Exploring Premium REITs for Reliable Cash Flow Generation

Updated Category News Views 196

Understanding High-Yield REIT Investments Investing in high-yield real estate investment trusts (REITs) is a popular strategy for those seeking attractive dividend income. REITs are uniquely designed to channel income back to their shareholders, making them an appealing choice for generating passive income streams. This article will explore several high-yield REITs that...

Continue Reading
Orchestra BioMed Strengthens Board with Industry Veteran

Updated Category News Views 180

Introduction of Christopher Cleary to the Orchestra BioMed Board Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is thrilled to announce a significant addition to its Board of Directors. Christopher Cleary, a monumental figure in the medical device industry, has joined the team as an independent member effective January 30, 2025. With over three decades of experience in...

Continue Reading
Microsoft's Latest Buyback Plan: What Investors Should Know

Updated Category News Views 202

Microsoft's Strategic Financial Moves Microsoft is making significant investments in its key areas while also ensuring it rewards its shareholders. As the tech giant ramps up its capital expenditures to improve cloud infrastructure—especially for artificial intelligence (AI)—it’s also keen on providing returns to its investors. Recently, the company announced a 10%...

Continue Reading